FibroGen, Inc (FGEN)

Etorro trading 970x250
FibroGen, Inc (FGEN) Logo

About FibroGen, Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Address: 409 Illinois Street, San Francisco, CA, United States, 94158

FibroGen, Inc News and around…

Latest news about FibroGen, Inc (FGEN) common stock and company :

Woodstock Corp Buys Amgen Inc, Applied Materials Inc, FedEx Corp, Sells Reata Pharmaceuticals ...
07 Jan, 2022 Yahoo! Finance

Boston, MA, based Investment company Woodstock Corp (Current Portfolio) buys Amgen Inc, Applied Materials Inc, FedEx Corp, Southwestern Energy Co, Sun Life Financial Inc, sells Reata Pharmaceuticals Inc, Aldeyra Therapeutics Inc, Epizyme Inc, International Business Machines Corp, Omnicom Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Woodstock Corp.

FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
04 Jan, 2022 Yahoo! Finance

SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13. The on-demand webcast of the session will be available on January 10 at 7:00am EST. The audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will

Does FibroGen (NASDAQ:FGEN) Have A Healthy Balance Sheet?
01 Jan, 2022 Yahoo! Finance

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
20 Dec, 2021 Yahoo! Finance

Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipelineHiFiBiO to receive $35 million option exercise payment, potential milestones and royalties SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), a leading biopharmaceutical company discovering, developing, and commercializing first-in-class therapeutics, and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherape

FIBROGEN ALERT: Bragar Eagel & Squire, P.C. Is Investigating Fibrogen, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
16 Dec, 2021 FinancialContent

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fibrogen, Inc. (NASDAQ: FGEN) on behalf of long-term stockholders following a class action complaint that was filed against Fibrogen on April 12, 2021. Our investigation concerns whether the board of directors of Fibrogen have breached their fiduciary duties to the company.

First Week of FGEN January 2022 Options Trading
29 Nov, 2021 FinancialContent

Investors in FibroGen Inc (FGEN) saw new options begin trading this week, for the January 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FGEN options chain for the new January 2022 contracts and identified one put and one call contract of particular interest.

Blade Therapeutics Appoints Bassem Elmankabadi, M.D., as Senior Vice President of Clinical Development
18 Nov, 2021 FinancialContent

Blade Therapeutics announces the appointment of Bassem Elmankabadi, M.D., as senior vice president of clinical development

S.F. biotech cutting 100 positions as it awaits U.S. fate of anemia drug
10 Nov, 2021 Yahoo! Finance

The drug is approved in Europe and China to treat chronic kidney disease patients with anemia, but likely will need to undertake another clinical trial in the United States to appease the Food and Drug Administration.

FibroGen, inc (FGEN) Q3 2021 Earnings Call Transcript
10 Nov, 2021 FinancialContent

FGEN earnings call for the period ending September 30, 2021.

FibroGen (FGEN) Q3 Earnings and Revenues Surpass Estimates
09 Nov, 2021 Yahoo! Finance

FibroGen (FGEN) delivered earnings and revenue surprises of 500.00% and 15.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

FibroGen Reports Third Quarter 2021 Financial Results
09 Nov, 2021 Yahoo! Finance

Roxadustat Receives EU approval for Patients with Anemia of CKD, triggering a $120M milestone payment from AstellasRoxadustat net product revenue in China of $13.4 million, on a US GAAP basis. Total roxadustat net sales in China of $57.8 million1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2021 and provided an update on the Co

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
09 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For ...

Analysts Predict 45% Upside For The Holdings of IDNA
08 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Genomics Immunology and Healthcare ETF (IDNA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $70.94 per unit.

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
08 Nov, 2021 FinancialContent

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good ...

FibroGen (FGEN) Expected to Beat Earnings Estimates: Should You Buy?
02 Nov, 2021 Yahoo! Finance

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors in FibroGen (NASDAQ:FGEN) have unfortunately lost 72% over the last three years
02 Nov, 2021 Yahoo! Finance

FibroGen, Inc. ( NASDAQ:FGEN ) shareholders should be happy to see the share price up 13% in the last month. But that...

FibroGen to Present at Upcoming Investor Conferences
02 Nov, 2021 Yahoo! Finance

SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following healthcare conferences: Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16 at 4:40 PM EST.12th Annual Jefferies London Healthcare Conference on Thursday, November 18 at 3:00 AM EST. An audio webcast will be available on the “Events & Presentations” section of the FibroGen Investor webpage

FibroGen to Report Third Quarter 2021 Financial Results
26 Oct, 2021 Yahoo! Finance

SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the FibroGen website

FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021
25 Oct, 2021 Yahoo! Finance

SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American Society of Nephrology Kidney Week 2021 taking place virtually November 4 - 7, 2021. A total of 18 presentations will be presented by FibroGen, or its collaboration partners AstraZeneca and Astellas Pharma, Inc., at this year’s meeting. Eleven of the presentations are related to phase 3 studies of roxadu

Can FibroGen (FGEN) Climb 136% to Reach the Level Wall Street Analysts Expect?
21 Oct, 2021 Yahoo! Finance

The mean of analysts' price targets for FibroGen (FGEN) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

First Week of June 2022 Options Trading For FibroGen (FGEN)
15 Oct, 2021 FinancialContent

Investors in FibroGen Inc (FGEN) saw new options begin trading this week, for the June 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 245 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Cibus Appoints Co-Founder Rory Riggs, as Chief Executive Officer
07 Oct, 2021 FinancialContent

Since its founding, Rory has been an important strategic partner in the success of Cibus.

SMLV's Underlying Holdings Imply 10% Gain Potential
07 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— SSGA US Small Cap Low Volatility Index ETF (SMLV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $125.23 per unit.

First Week of FGEN October 15th Options Trading
06 Oct, 2021 FinancialContent

Investors in FibroGen Inc (FGEN) saw new options begin trading this week, for the October 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FGEN options chain for the new October 15th contracts and identified the following call contract of particular interest.

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
05 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Thursday's After-Market Session
30 Sep, 2021 FinancialContent

Gainers FibroGen (NASDAQ:FGEN) stock moved upwards by 4.99% to $10.73 during Thursday's after-market session. The company's market ...

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
23 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

50 Biggest Movers From Yesterday
23 Sep, 2021 FinancialContent

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares jumped 61.9% to close at $9.21 on Wednesday following an announcement ...

Why FibroGen Fell by More Than 9% on Wednesday
22 Sep, 2021 FinancialContent

A noted investment bank takes a dimmer view of the company's stock.

32 Stocks Moving In Wednesday's Mid-Day Session
22 Sep, 2021 FinancialContent

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 53.1% to $8.71 following an announcement from management that ...

FibroGen, Inc (FGEN) is a NASDAQ Common Stock listed in , ,

970x250